CD22 and Autoimmune Disease

REFERENCES

• Fiorina P, Sayegh MH. B cell-targeted therapies in autoimmunity: rationale and progress. F1000 Biol Rep. 2009;1:39–42.
   PubMedGoogle Scholar
• Crampton SP, Voynova E, Bolland S. Innate pathways to B-cell activation and tolerance. Ann N Y Acad Sci. 2010;1183:58–68.
   PubMed Web of Science ®Google Scholar
• Levesque MC. Translational Mini-Review Series on B Cell-Directed Therapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol. 2009;157:198–208.
   PubMed Web of Science ®Google Scholar
• Poe JC, Hasegawa M, Tedder TF. CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction. Int Rev Immunol. 2001;20:739–762.
   PubMedGoogle Scholar
• Pritchard NR, Smith KGC. B cell inhibitory receptors and autoimmunity. Immunology. 2003;108:263–273.
   PubMedGoogle Scholar
• Cyster JG, Goodnow CC. Tuning antigen receptor signaling by CD22: integrating cues from antigens and the microenvironment. Immunity. 1997;6:509–517.
   PubMed Web of Science ®Google Scholar
• Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997;15:481–504.
   PubMed Web of Science ®Google Scholar
• Sato S, Miller AS, Inaoki M, CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity. 1996;5:551–562.
   PubMed Web of Science ®Google Scholar
• Nitschke L. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opin Immunol. 2005;17:290–297.
   PubMed Web of Science ®Google Scholar
• Grimaldi CM, Hicks R, Diamond B. B cell selection and susceptibility to autoimmunity. J Immunol. 2005;174:1775–1781.
   PubMedGoogle Scholar
• Walker JA, Smith KG. CD22: an inhibitory enigma. Immunology. 2008;123:314–325.
   PubMed Web of Science ®Google Scholar
• Pezzutto A, Dorken B, Moldenhauer G, Clark EA. Amplification of human B cell activation by a monoclonal antibody to the B cell-specific antigen CD22, Bp 130/140. J Immunol. 1987;138:98–103.
   PubMed Web of Science ®Google Scholar
• Pezzutto A, Rabinovitch PS, Dorken B, Moldenhauer G, Clark EA. Role of the CD22 human B cell antigen in B cell triggering by anti-immunoglobulin. J Immunol. 1988;140:1791–1795.
   PubMed Web of Science ®Google Scholar
• Stamenkovic I, Seed B. The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion. Nature. 1990;345:74–77.
   PubMed Web of Science ®Google Scholar
• Wilson GL, Fox CH, Fauci AS, Kehrl JH. cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions. J Exp Med. 1991;173:137–146.
   PubMedGoogle Scholar
• Tedder TF, Poe JC, Haas KM. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol. 2005;88:1–50.
   PubMed Web of Science ®Google Scholar
• Daridon C, Blassfeld D, Reiter K, Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12:R204.
   PubMed Web of Science ®Google Scholar
• Nitschke L, Carsetti R, Ocker B, Kohler G, Lamers MC. CD22 is a negative regulator of B-cell receptor signalling. Curr Biol. 1997;7:133–143.
   PubMed Web of Science ®Google Scholar
• Smith KGC, Hewitson TD, Nossal GJ, Tarlinton DM. The phenotype and fate of the antibody-forming cells of the splenic foci. Eur J Immunol. 1996;26:444–448.
   PubMed Web of Science ®Google Scholar
• Wen T, Mingler MK, Blanchard C, The pan-B cell marker CD22 is expressed on gastrointestinal eosinophils and negatively regulates tissue eosinophilia. J Immunol. 2012;188:1075–1082.
   PubMedGoogle Scholar
• Sgroi D, Varki A, Braesch-Andersen S, Stamenkovic I. CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin. J Biol Chem. 1993;268:7011–7018.
   PubMedGoogle Scholar
• von Gunten S, Bochner BS. Basic and clinical immunology of Siglecs. Ann N Y Acad Sci. 2008;1143:61–82.
   PubMed Web of Science ®Google Scholar
• Powell LD, Jain RK, Matta KL, Sabesan S, Varki A. Characterization of sialyloligosaccharide binding by recombinant soluble and native cell-associated CD22: evidence for a minimal structural recognition motif and the potential importance of multisite binding. J Biol Chem. 1995;270:7523–7532.
   PubMedGoogle Scholar
• Hanasaki K, Powell LD, Varki A. Binding of human plasma sialoglycoproteins by the B cell-specific lectin CD22: selective recognition of immunoglobulin M and haptoglobin. J Biol Chem. 1995;270:7543–7550.
   PubMedGoogle Scholar
• Powell LD, Sgroi D, Sjoberg ER, Stamenkovic I, Varki A. Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition. J Biol Chem. 1993;268:7019–7027.
   PubMed Web of Science ®Google Scholar
• Jellusova J, Nitschke L. Regulation of b cell functions by the sialic acid-binding receptors Siglec-G and CD22. Front Immunol. 2011;2:96.
   PubMedGoogle Scholar
• Engel P, Wagner N, Miller AS, Tedder TF. Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. J Exp Med. 1995;181:1581–1586.
   PubMed Web of Science ®Google Scholar
• Law CL, Aruffo A, Chandran KA, Doty RT, Clark EA. Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells. J Immunol. 1995;155:3368–3376.
   PubMed Web of Science ®Google Scholar
• Nath D, van der Merwe PA, Kelm S, Bradfield P, Crocker PR. The amino-terminal immunoglobulin-like domain of sialoadhesin contains the sialic acid binding site: comparison with CD22. J Biol Chem. 1995;270:26184–26191.
   PubMedGoogle Scholar
• van der Merwe PA, Crocker PR, Vinson M, Localization of the putative sialic acid-binding site on the immunoglobulin superfamily cell-surface molecule CD22. J Biol Chem. 1996;271:9273–9280.
   PubMedGoogle Scholar
• Flaswinkel H, Reth M. Dual role of the tyrosine activation motif of the Ig-alpha protein during signal transduction via the B cell antigen receptor. EMBO J. 1994;13:83–89.
   PubMed Web of Science ®Google Scholar
• Smith KGC, Tarlinton DM, Doody GM, Hibbs ML, Fearon DT. Inhibition of the B cell by CD22: a requirement for Lyn. J Exp Med. 1998;187:807–811.
   PubMed Web of Science ®Google Scholar
• Cornall RJ, Cyster JG, Hibbs ML, Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity. 1998;8:497–508.
   PubMed Web of Science ®Google Scholar
• Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM. Lyn tyrosine kinase: accentuating the positive and the negative. Immunity. 2005;22:9–18.
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Kuwano Y, Watanabe R, B cell antigen receptor and CD40 differentially regulate CD22 tyrosine phosphorylation. J Immunol. 2006;176:873–879.
   PubMed Web of Science ®Google Scholar
• Leprince C, Draves KE, Geahlen RL, Ledbetter JA, Clark EA. CD22 associates with the human surface IgM-B-cell antigen receptor complex. Proc Natl Acad Sci U S A. 1993;90:3236–3240.
   PubMedGoogle Scholar
• Doody GM, Justement LB, Delibrias CC, A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science. 1995;269:242–244.
   PubMed Web of Science ®Google Scholar
• Sato S, Jansen PJ, Tedder TF. CD19 and CD22 expression reciprocally regulates tyrosine phosphorylation of Vav protein during B lymphocyte signaling. Proc Natl Acad Sci U S A. 1997;94: 13158–13162.
   PubMedGoogle Scholar
• Fujimoto M, Bradney AP, Poe JC, Steeber DA, Tedder TF. Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop. Immunity. 1999;11:191–200.
   PubMed Web of Science ®Google Scholar
• Gerlach J, Ghosh S, Jumaa H, B cell defects in SLP65/BLNK-deficient mice can be partially corrected by the absence of CD22, an inhibitory coreceptor for BCR signaling. Eur J Immunol. 2003;33:3418–3426.
   PubMedGoogle Scholar
• Jellusova J, Duber S, Guckel E, Siglec-G regulates B1 cell survival and selection. J Immunol. 2010;185:3277–3284.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Deb J, Patra AK, NFATc1 affects mouse splenic B cell function by controlling the calcineurin–NFAT signaling network. J Exp Med. 2011;208:823–839.
   PubMedGoogle Scholar
• Chen J, McLean PA, Neel BG, CD22 attenuates calcium signaling by potentiating plasma membrane calcium-ATPase activity. Nat Immunol. 2004;5:651–657.
   PubMed Web of Science ®Google Scholar
• Law CL, Sidorenko SP, Chandran KA, CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation. J Exp Med. 1996;183:547–560.
   PubMedGoogle Scholar
• Tuscano JM, Engel P, Tedder TF, Agarwal A, Kehrl JH. Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22. Eur J Immunol. 1996;26:1246–1252.
   PubMedGoogle Scholar
• Wienands J, Freuler F, Baumann G. Tyrosine-phosphorylated forms of Ig beta, CD22, TCR zeta and HOSS are major ligands for tandem SH2 domains of Syk. Int Immunol. 1995;7:1701–1708.
   PubMedGoogle Scholar
• Brauweiler AM, Tamir I, Cambier JC. Bilevel control of B-cell activation by the inositol 5-phosphatase SHIP. Immunol Rev. 2000;176:69–74.
   PubMedGoogle Scholar
• Stork B, Engelke M, Frey J, Grb2 and the non-T cell activation linker NTAL constitute a Ca(2+)-regulating signal circuit in B lymphocytes. Immunity. 2004;21:681–691.
   PubMed Web of Science ®Google Scholar
• O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Hyperresponsive B cells in CD22-deficient mice. Science. 1996;274:798–801.
   PubMed Web of Science ®Google Scholar
• Otipoby KL, Andersson KB, Draves KE, CD22 regulates thymus-independent responses and the lifespan of B cells. Nature. 1996;384:634–637.
   PubMed Web of Science ®Google Scholar
• Poe JC, Haas KM, Uchida J, Severely impaired B lymphocyte proliferation, survival, and induction of the c-Myc:Cullin 1 ubiquitin ligase pathway resulting from CD22 deficiency on the C57BL/6 genetic background. J Immunol. 2004;172:2100–2110.
   PubMedGoogle Scholar
• Samardzic T, Marinkovic D, Danzer CP, Reduction of marginal zone B cells in CD22-deficient mice. Eur J Immunol. 2002;32:561–567.
   PubMed Web of Science ®Google Scholar
• Pillai S. Two lymphoid roads diverge–but does antigen bade B cells to take the road less traveled? Immunity. 2005;23:242–244.
   PubMed Web of Science ®Google Scholar
• Wen L, Brill-Dashoff J, Shinton SA, Evidence of marginal-zone B cell-positive selection in spleen. Immunity. 2005;23:297–308.
   PubMedGoogle Scholar
• Cariappa A, Tang M, Parng C, The follicular versus marginal zone B lymphocyte cell fate decision is regulated by Aiolos, Btk, and CD21. Immunity. 2001;14:603–615.
   PubMed Web of Science ®Google Scholar
• Collins BE, Smith BA, Bengtson P, Paulson JC. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat Immunol. 2006;7:199–206.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Bandulet C, Nitschke L. Regulation of B cell development and B cell signalling by CD22 and its ligands alpha2,6-linked sialic acids. Int Immunol. 2006;18:603–611.
   PubMedGoogle Scholar
• Hennet T, Chui D, Paulson JC, Marth JD. Immune regulation by the ST6Gal sialyltransferase. Proc Natl Acad Sci U S A. 1998;95:4504–4509.
   PubMedGoogle Scholar
• Jin L, McLean PA, Neel BG, Wortis HH. Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling. J Exp Med. 2002;195:1199–1205.
   PubMed Web of Science ®Google Scholar
• Grewal PK, Boton M, Ramirez K, ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling. Mol Cell Biol. 2006;26:4970–4981.
   PubMed Web of Science ®Google Scholar
• Onodera T, Poe JC, Tedder TF, Tsubata T. CD22 regulates time course of both B cell division and antibody response. J Immunol. 2008;180:907–913.
   PubMed Web of Science ®Google Scholar
• Poe JC, Fujimoto Y, Hasegawa M, CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat Immunol. 2004;5:1078–1087.
   PubMed Web of Science ®Google Scholar
• Goodnow CC, Crosbie J, Adelstein S, Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature. 1988;334:676–682.
   PubMed Web of Science ®Google Scholar
• Kawasaki N, Rademacher C, Paulson JC. CD22 Regulates Adaptive and Innate Immune Responses of B Cells. J Innate Immun. 2011;3:411–419.
   PubMed Web of Science ®Google Scholar
• Kelm S, Gerlach J, Brossmer R, Danzer CP, Nitschke L. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J Exp Med. 2002;195:1207–1213.
   PubMed Web of Science ®Google Scholar
• Razi N, Varki A. Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc Natl Acad Sci U S A. 1998;95:7469–7474.
   PubMed Web of Science ®Google Scholar
• Razi N, Varki A. Cryptic sialic acid binding lectins on human blood leukocytes can be unmasked by sialidase treatment or cellular activation. Glycobiology. 1999;9:1225–1234.
   PubMed Web of Science ®Google Scholar
• Danzer CP, Collins BE, Blixt O, Paulson JC, Nitschke L. Transitional and marginal zone B cells have a high proportion of unmasked CD22: implications for BCR signaling. Int Immunol. 2003;15:1137–1147.
   PubMedGoogle Scholar
• Peaker CJ, Neuberger MS. Association of CD22 with the B cell antigen receptor. Eur J Immunol. 1993;23:1358–1363.
   PubMedGoogle Scholar
• Zhang M, Varki A. Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis. Glycobiology. 2004;14:939–949.
   PubMedGoogle Scholar
• Han S, Collins BE, Bengtson P, Paulson JC. Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking. Nat Chem Biol. 2005;1:93–97.
   PubMed Web of Science ®Google Scholar
• Nitschke L, Floyd H, Ferguson DJ, Crocker PR. Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells. J Exp Med. 1999;189:1513–1518.
   PubMed Web of Science ®Google Scholar
• Lanoue A, Batista FD, Stewart M, Neuberger MS. Interaction of CD22 with alpha2,6-linked sialoglycoconjugates: innate recognition of self to dampen B cell autoreactivity? Eur J Immunol. 2002;32:348–355.
   PubMedGoogle Scholar
• Aruffo A, Kanner SB, Sgroi D, Ledbetter JA, Stamenkovic I. CD22-mediated stimulation of T cells regulates T-cell receptor/CD3-induced signaling. Proc Natl Acad Sci U S A. 1992;89:10242–10246.
   PubMedGoogle Scholar
• Sgroi D, Koretzky GA, Stamenkovic I. Regulation of CD45 engagement by the B-cell receptor CD22. Proc Natl Acad Sci U S A. 1995;92:4026–4030.
   PubMedGoogle Scholar
• Tuscano J, Engel P, Tedder TF, Kehrl JH. Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation. Blood. 1996;87:4723–4730.
   PubMedGoogle Scholar
• Floyd H, Nitschke L, Crocker PR. A novel subset of murine B cells that expresses unmasked forms of CD22 is enriched in the bone marrow: implications for B-cell homing to the bone marrow. Immunology. 2000;101:342–347.
   PubMed Web of Science ®Google Scholar
• Collins BE, Blixt O, Han S, High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J Immunol. 2006;177:2994–3003.
   PubMed Web of Science ®Google Scholar
• Collins BE, Blixt O, DeSieno AR, Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc Natl Acad Sci U S A. 2004;101:6104–6109.
   PubMedGoogle Scholar
• Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15:308–318.
   PubMed Web of Science ®Google Scholar
• Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929–939.
   PubMed Web of Science ®Google Scholar
• Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity: insights from the clinic. Immunity. 2004;20:517–527.
   PubMed Web of Science ®Google Scholar
• Mok MY. The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum Dis. 2010;13:3–11.
   PubMed Web of Science ®Google Scholar
• Harley IT, Kaufman KM, Langefeld CD, Harley JB, Kelly JA. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat Rev Genet. 2009;10:285–290.
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673–2677.
   PubMed Web of Science ®Google Scholar
• Looney RJ, Anolik JH, Campbell D, B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580–2589.
   PubMed Web of Science ®Google Scholar
• Dorner T, Kinnman N, Tak PP. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther. 2010;125:464–475.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Anolik JH. B-cell biology and related therapies in systemic lupus erythematosus. Rheum Dis Clin North Am. 2010;36:109–130, viii–ix.
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526–1533.
   PubMed Web of Science ®Google Scholar
• Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity. 2000;13:277–285.
   PubMed Web of Science ®Google Scholar
• Strasser A, Whittingham S, Vaux DL, Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A. 1991;88:8661–8665.
   PubMed Web of Science ®Google Scholar
• Gross JA, Johnston J, Mudri S, TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995–999.
   PubMed Web of Science ®Google Scholar
• Stohl W, Metyas S, Tan SM, B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003;48:3475–3486.
   PubMed Web of Science ®Google Scholar
• Thien M, Phan TG, Gardam S, Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20:785–798.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–731.
   PubMed Web of Science ®Google Scholar
• O'Keefe TL, Williams GT, Batista FD, Neuberger MS. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med. 1999;189:1307–1313.
   PubMed Web of Science ®Google Scholar
• Nitschke L, Lajaunias F, Moll T, Expression of aberrant forms of CD22 on B lymphocytes in Cd22a lupus-prone mice affects ligand binding. Int Immunol. 2006;18:59–68.
   PubMedGoogle Scholar
• Kikuchi S, Fossati-Jimack L, Moll T, Differential role of three major New Zealand Black-derived loci linked with Yaa-induced murine lupus nephritis. J Immunol. 2005;174:1111–1117.
   PubMedGoogle Scholar
• Kikuchi S, Amano H, Amano E, Identification of 2 major loci linked to autoimmune hemolytic anemia in NZB mice. Blood. 2005;106:1323–1329.
   PubMed Web of Science ®Google Scholar
• Lajaunias F, Ibnou-Zekri N, Fossati JL, Polymorphisms in the Cd22 gene of inbred mouse strains. Immunogenetics. 1999;49:991–995.
   PubMed Web of Science ®Google Scholar
• Hibbs ML, Tarlinton DM, Armes J, Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell. 1995;83:301–311.
   PubMed Web of Science ®Google Scholar
• Silver K, Bouriez-Jones T, Crockford T, Spontaneous class switching and B cell hyperactivity increase autoimmunity against intracellular self antigen in Lyn-deficient mice. Eur J Immunol. 2006;36:2920–2927.
   PubMedGoogle Scholar
• Carnahan J, Wang P, Kendall R, Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003;9:3982S–3990S.
   PubMed Web of Science ®Google Scholar
• O'Reilly MK, Tian H, Paulson JC. CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells. J Immunol. 2011;186:1554–1563.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115–123.
   PubMed Web of Science ®Google Scholar
• Conti F, Perricone C, Ceccarelli F, Valesini G. Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin. Autoimmun Rev. 2010;9:716–720.
   PubMed Web of Science ®Google Scholar
• Emery P, Deodhar A, Rigby WF, Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69:1629–1635.
   PubMed Web of Science ®Google Scholar
• Jones RB, Ferraro AJ, Chaudhry AN, A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60:2156–2168.
   PubMed Web of Science ®Google Scholar
• Ding C, Foote S, Jones G. B-cell-targeted therapy for systemic lupus erythematosus: an update. BioDrugs. 2008;22:239–249.
   PubMed Web of Science ®Google Scholar
• Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford). 2011;50:222–229.
   PubMed Web of Science ®Google Scholar
• Tony HP, Burmester G, Schulze-Koops H, Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011;13:R75.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum. 2012;64:1215–1226.
   PubMed Web of Science ®Google Scholar
• Dorner T, Kaufmann J, Wegener WA, Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8:R74.
   PubMed Web of Science ®Google Scholar
• Jacobi AM, Goldenberg DM, Hiepe F, Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis. 2008;67:450–457.
   PubMed Web of Science ®Google Scholar
• Carnahan J, Stein R, Qu Z, Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol. 2007;44:1331–1341.
   PubMed Web of Science ®Google Scholar
• Sieger N, Reiter K, Mei HE, Epratuzumab inhibits upstream B cell receptor (BCR) signaling and modulates Ca2+ flux upon activation. Presented at ACR 2011: Poster 1742.
   Google Scholar
• Kalunian K, Wallace DJ, Petri M, BILAG-measured improvement in moderately and severely affected body systems in patients with systemic lupus erythematosus (SLE) by epratuzumab: results from EMBLEM, a phase IIb study. Presented at EULAR 2010, Rome, Italy, 16–19 June 2010.
   Google Scholar
• Wallace DJ, Kalunian K, Petri M, Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study. Presented at World Lupus Congress 2010.
   Google Scholar
• Wallace DJ, Strand V, Furie R, Evaluation of treatment success in systemic lupus erythematosus clinical trials: development of the British Isles Lupus Assessment Group-based Composite Lupus Assessment Endpoint. Presented at ACR 2011: Poster 2265.
   Google Scholar
• Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther. 2006;6:1341–1353.
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Tant L, Burmester GR, Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006;8:R129.
   PubMed Web of Science ®Google Scholar